Volumen: 16 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2012
Authors: Dourisboure R.
Abstract: Patients with acute leukemia and normal karyotype
(AML-NK) are classified in an intermediate risk group
(approximately 40-50%) with a variable disease free
survival period probably due to their molecular heterogeneity.
Somatic mutations have been identified in
several genes: FLT3, NPM1, CEBPA, MLL, NRAS, KIT,
WT1, RUNX1, TET2, IDH1/2, DNMT3A, ASXL1, PHF6
with different prognosis impact. Thereby, mutations in
FLT3 (37%-46% of patients) have negative prognostic
impact while the opposite occur with mutations in
NPM1 (48%-53% of patients) and CEBPA (13%-15% of
patients).
Key words: acute leukemia, prognosis, FLT3, NPM1,
CEBPA
Pages : 200-202
|
